Atkins et al.,[14] reported that the level of CAIX in RCC tissues might also serve as a useful predictor of the response to IL-2 therapy and suggested that CAIX might maintain balanced pH in the tumor microenvironment, which might in turn be favorable for the maintenance of immune effector mechanisms. The gene discussed is CA9; the disease is neoplasm.